baber/WOPTO huggingface dataset:
Patent FI-933330-A0 (FI)
Inventor: OSHLACK BENJAMIN
IPC: A61K47/44
Filed: 1993-07-23
Abstract: (A) Controlled release oxycodone formulation for oral admin. to human patients, comprises (i) 10-40mg oxycodone or its salt, the formulation providing a mean max. plasma conc. of oxycodone of 6-60 ng/ml from a mean of 2-4.5 hrs.. After admin., and a mean min. plasma conc. of 3-30 ng/ml from a mean of 10-14 hrs. after repeated admin. every 12 hrs. through steady state conditions. (ii) 10-160 mg oxycodone or its salt, the formulation providing a mean max. plasma conc. of oxycodone of 6-240 ng/ml from a mean of 2-4.5 hrs. after admin., and a mean min. plasma conc. from 3-120 ng/ml from a mean of 10-14 hrs. after repeated admin. every 12 hrs. through steady-state conditions. (B) Also claimed is a solid controlled release oral dosage form comprising (i) oxycodone or its salt in amt. of 10-160 mg; a controlled release matrix selected from hydrophilic hydrophobic polymers, digestible opt. substd. 8-50C hydrocarbons, and/or polyalkylene glycols; and a diluent; wherein the compsn. provides a mean max. plasma conc. of oxycodone of 6-240 ng/ml from a mean of 2-4.5 hrs. after admin, and mean min. plasma conc. of 3-120 ng/ml from a mean of 10-14 hrs. after repeated admin. every 12 hrs. through steady-state conditions; or (ii) an analgesically effective amt. of spheroids comprising oxycodone or its salt and either a spheronising agent or an acrylic polymer or copolymer, such that the total dosage of oxycodone in the dosage form is 10-160 mg; a film coating which controls the release of the oxycodone or its salt at a controlled rate in an aq. medium, wherein the compsn. provides an in vitro dissolution rate of the dosage form.
Patent FI-945608-A0 (FI)
Inventor: JENKINS RICHARD DUANE
IPC: C08F290/06
Filed: 1994-11-28
Abstract: This invention relates to polymers which comprise the reaction product of: (A) about 0-99.9 weight percent of one or more nonionic, cationic, anionic or amphoteric monomers; (B) about 0-99.9 weight percent of one or more monoethylenically unsaturated monomers different from (A); (C) about 0.1-100 weight percent of one or more monoethylenically unsaturated macromonomers different from (A) and (B); and (D) about 0-20 weight percent or greater of one or more polyethylenically unsaturated monomers different from (A), (B) and (C). When the polymers are added to latex paints and the pH adjusted, the viscosity of the paint is increased, brush drag is increased, and the paint rheology is otherwise improved. This invention also relates to macromonomer compounds useful as copolymerizable monomers in various polymerization methods and as emulsifiers in the emulsion or suspension polymerization of various monomers to produce an aqueous suspension of polymer particles. This invention further relates to complex hydrophobe compounds and to alkoxylation products, i.e., condensation reaction products of alkylene oxides and complex hydrophobe compounds having at least one active hydrogen and to alkoxylation products.
Patent FI-963076-A0 (FI)
Inventor: KARLSSON HANS
IPC: A61M25/06
Filed: 1996-08-02
Abstract: PCT No. PCT/SE95/00096 Sec. 371 Date Jul. 31, 1996 Sec. 102(e) Date Jul. 31, 1996 PCT Filed Feb. 1, 1995 PCT Pub. No. WO95/20991 PCT Pub. Date Aug. 10, 1995A dialysis probe combination with a microdialysis probe (1) which can be inserted into tissue with the aid of an insertion device that includes a canula tube (9). In order to be able to remove the canula tube (9) after insertion, the tube is provided with a slot along the whole of its length, this slot preferably including an angle of about 65 DEG  in the radial direction. During insertion, the probe is held within the canula tube by virtue of the major part of the probe being larger than the slot. However, the proximal portion of the probe includes a flattened part which is able to pass through the slot, and the canula tube can be drawn past the flattened part by lifting this part, while leaving the probe in the tissue.
Patent FI-963222-A0 (FI)
Inventor: ARTIS DEAN R
IPC: C07D307/88
Filed: 1996-08-16
Abstract: The disclosed derivatives of mycophenolic acid are therapeutic agents advantageous in the treatment of disease states indicated for mycophenolic acid and/or mycophenolate mofetil and other immunosuppressant agents.
Patent IL-61165-A0 (IL)
Title: Process for the production of ammonia and hydrogen chloride
IPC: C01B21/087
Filed: 1980-09-30
Abstract: According to the present invention, ammonia and hydrogen chloride are prepared from ammonium chloride. The steps of the process include: 1. heating a mixture consisting essentially of (a) ammonium chloride, (b) a water-insoluble amine, and (c) an organic solvent; 2. evacuating the ammonia released thereby; 3. removing the polar solvent and any water remaining in the sump to the extent possible and/or required; and 4. heating the residue containing a non-polar and/or a weakly polar solvent and removing the hydrogen chloride.
Patent IL-67670-A0 (IL)
Title: Non-woven material for medical compresses
IPC: A61L15/16
Filed: 1983-01-12
Abstract: PCT No. PCT/FR82/00211 Sec. 371 Date Sep. 28, 1983 Sec. 102(e) Date Sep. 28, 1983 PCT Filed Dec. 16, 1982 PCT Pub. No. WO83/02630 PCT Pub. Date Aug. 4, 1983.Curled non-woven material formed of waves such as contiguous anti-nodes (9,10) of adjacent waves consist of small adjacent pads (11,12) located on the same side of the median plan (8) of the non-woven material. Use: Medical and surgical compresses FIG. 3.
Patent IL-71544-A0 (IL)
Title: Metallization of thin,electrically isolating films
IPC: B32B15/08
Filed: 1984-04-13
Abstract: Electrically insulating polymeric film substrates are conductively metallized, e.g., to provide base members useful in the fabrication of printed circuits and the like, by (1) shaping into such film substrate an intimate homogeneous admixture of a film-forming polymer matrix having from 10 to 70 percent by total weight of said admixture of finely divided, non-conductive metal oxide particles uniformly distributed therein, (2) disrupting at least one face surface of said shaped film substrate to expose thereon a plurality of said finely divided, non-conductive metal oxide particles, (3) treating said at least one disrupted face surface with a preferably borohydride reducing agent to reduce said exposed metal oxide particles into a layer of electrically conductive free metal, whereby said at least one face surface is rendered electrically conductive, and, advantageously, (4) eletrolytically depositing a reinforcing, electrically conductive metallic overlayer atop said first layer of electrically conductive free metal.
Patent IL-87062-A0 (IL)
Title: Extrusion die for protrusion and/or high cell density ceramic honeycomb structures
IPC: B28B3/26
Filed: 1988-07-11
Abstract: Secondary discharge slots (2) are cut into the face (1) of newly made or used extrusion dies such that the secondary discharge slots (2) communicate transversely and longitudinally with primary discharge slots (3) but do not communicate with the feed holes (7). An extrusion die arrangement is set forth for the production of ceramic honeycomb structures which produce a greater number of cells per square inch, protrusions on the cell walls, or a combination of both dependent upon the Primary Slots' Volume to Secondary Slots' Volume ratio. The secondary discharge slots 2) can produce honeycomb substrates with much greater surface areas, using an extrusion die with a significantly reduced number of feed holes (7) and a greater number of discharge slots.
Patent IL-91369-A0 (IL)
Title: Lfa-1alpha subunit and derivatives thereof free of natural contaminants,and pharmaceutical compositions containing it
IPC: A61P37/08
Filed: 1989-08-21
Abstract: The present invention relates to LFA-1 alpha-subunit which is involved in the process through which cell recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, the functional derivatives of such molecules, screening assays for identifying such molecules and therapeutic and diagnostic uses for such molecules.
Patent IL-94250-A0 (IL)
Title: Non-linear optically active materials
IPC: C08G18/67
Filed: 1990-05-01
Abstract: Materials active in nonlinear optics exhibiting very good filmogibility and a high optical activity. This material has a unit of the following formula: 
<IMAGE>
 in which:
 - R1 and R2, which are identical or different, denote a linear or branched methylene chain containing 2 to 6 carbon atoms
 - R3 is an aliphatic, aromatic or arylaliphatic hydrocarbon radical
 - R4 and R5, which are identical or different, denote a nitrogen atom or the (CH) group
 - Z1 and Z2, which are identical or different, denote an aromatic group containing at least one substituent R7 other than the radical A
 - A denotes an electron-accepting group, it being possible for the radical Z2 to carry a number of groups A.
Patent IL-99334-A0 (IL)
Title: Modular trial hip replacement system
IPC: A61F2/46
Filed: 1991-08-28
Abstract: A multi-piece trial femoral component kit is used for preparing and sizing a femoral cavity prior to implantation of a prosthetic femoral component. The trial component kit has at least three trial stem portions of differing size and at least three trial body portions of different size. The stem and body portions include mating male and female elements which allow the stem portions to be securely coupled to the body portions. In order to ensure that the so-coupled stem and body portions form a trial femoral component having a size equal to an available orthopedic femoral implant, the male and female elements include a key and keyway which are sized so that only trial stem and body portions resulting in an available femoral implant can be combined and used as a trial femoral component.
Patent AU-PO258196-A0 (AU)
Title: Method for determining ion channel activity of a substance
IPC: C12N15/09
Filed: 1996-09-27
Abstract: A method for determining the ion channel activity of a substance comprises the steps of (i) expressing the substance as a heterologous protein in a host cell, and (ii) determining changes in permeability of the plasma membrane of the host cell induced by expression of the heterologous protein. A screening method for determining ion channel modulating activity of a test substance is also disclosed.
Patent FI-20055239-A0 (FI)
Inventor: LAAKKONEN HARRI
IPC: H04L29/06
Filed: 2005-05-19
Abstract: A method for processing messages in a data processing device comprising, a data processing device and a computer program product. The device comprises a data transmission unit (106), which is configured to be connected to a data transmission system and to receive data including messages with the data transmission system; and a processing unit (102) connected to the data transmission unit for processing data, the processing unit being configured to control the processing of the received data in the decoding stack based on the decoding of the received data performed in the decoding layers, the decoding stack comprising at least a lower decoding layer and an upper decoding layer. The processing unit (102) is further configured to form the decoding stack such that at least one decoding layer comprises two or more decoding layers based on different protocols and at least one switching element, and is configured to detect a control command for controlling the processing of data in the decoding stack, and the switching element is configured to control the processing of data in the decoding stack on the basis of the detected control command.
Patent FI-20110200-A0 (FI)
Inventor: MAEKELAE TUOMO
IPC: C22B/
Filed: 2011-06-13
Abstract: The invention relates to a method for improving the reduction degree of metal components in a chromite concentrate when smelting ferroalloy suitable for manufacturing of stainless steel. The chromite concentrate is fed together with nickel-containing raw material so that by means the amount of nickel-containing raw material it is achieved a desired reduction degree for the metal components of ferroalloy.
Patent IL-101346-A0 (IL)
Title: Long-acting biodegradable microparticles and process for their preparation
IPC: A61K9/52
Filed: 1992-03-23
Abstract: Long-acting biodegradable microparticles containing therapeutically active peptides as active ingredient and poly(lactide-co-glycolide) as vehicle, which are obtained by spray drying at temperatures below 60 DEG C with a spray flow above 500 l(STP), are described.
Patent IL-107342-A0 (IL)
Title: Azacycloalkane derivatives, their preparation and pharmaceutical compositions containing them
IPC: A61P43/00
Filed: 1993-10-21
Abstract: The invention relates to arylidene-1-azacycloalkanes and arylalkyl-1-azacycloalkanes of the general formula <IMAGE>  in which n, m, p, A, W<1>, W<2>, X, Y and R<1> to R<11> are defined as in Claim 1, their isomers and isomer mixtures and their salts, which have useful properties and in particular exert an inhibitory action on cholesterol biosynthesis.
Patent IL-108836-A0 (IL)
Title: C9 taxane derivatives and pharmaceutical compositions containing them
IPC: C07D409/12
Filed: 1994-03-03
Abstract: Taxane derivatives, useful as anti-tumour and anti-leukemia agents, having alternative C9 substituents wherein the substituents are selected from a group consisting of hydrogen, hydroxy, protected hydroxy and acyloxy.
Patent IL-109395-A0 (IL)
Title: Heterocyclic derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
IPC: A61P37/08
Filed: 1994-04-22
Abstract: A compound of the formula : <CHEM>  wherein   X<1>   is N or C-R<6>, X<2>   is N or C-R<7>, X<3>   is N or C-R<8>, R<1>   is hydrogen or halogen, R<2>   is halogen, R<3>   is hydrogen, nitro, amino optionally having suitable substituent(s) or a heterocyclic group optionally having suitable substituent(s), R<4> and R<5>   are each hydrogen or halogen, R<6> and R<8>   are each hydrogen, halogen, lower alkyl, hydroxy, lower alkylthio, amino optionally substituted with lower alkyl, or lower alkoxy optionally substituted with a substituent selected from the group consisting of hydroxy, lower alkoxy, amino, lower alkylamino and aryl optionally substituted with lower alkoxy, R<7>   is hydrogen or lower alkyl, A   is lower alkylene, and Q   is O or N-R<9>, in which R<9> is hydrogen or acyl, provided that R<3> is not hydrogen when X<1> is C-R<6>, in which R<6> is hydrogen, and pharmaceutically acceptable salts thereof, processes for their preparation and pharmaceutical compositions comprising them.
Patent IL-110844-A0 (IL)
Title: Substituted benzodioxan compounds, processes for their preparation, and pharmaceutical compositions containing them
IPC: A61K31/495
Filed: 1994-09-02
Abstract: PCT No. PCT/EP94/02904 Sec. 371 Date Jun. 5, 1996 Sec. 102(e) Date Jun. 5, 1996 PCT Filed Sep. 1, 1994 PCT Pub. No. WO95/07274 PCT Pub. Date Mar. 16, 1995Compounds of formula I    <IMAGE>  I  and pharmaceutically acceptable salts thereof in which A is methylene or -O-; B is methylene or -O-; and g is 0, 1, 2, 3 or 4; R1, R2, R3, R4, U, Q and T are defined in claim 1. The compounds have utility in the treatment of central nervous system disorders, for example depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, Parkinson's disease, obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, senile dementia, obsessive-compulsive behaviour, panic attacks, eating disorders and anorexia, cardiovascular and cerebrovascular disorders, non-insulin dependent diabetes mellitus, hyperglycaemia, constipation, arrhythmia, disorders of the neuroendocrine system, stress, prostatic hypertrophy, and spasticity.
Patent IL-114663-A0 (IL)
Title: New derivatives of imidazole their preparation process the new intermediates obtained their use as medicaments and the pharmaceutical compositions containing them
IPC: A61K31/415
Filed: 1995-07-19
Abstract: PCT No. PCT/FR95/01033 Sec. 371 Date Jan. 31, 1997 Sec. 102(e) Date Jan. 31, 1997 PCT Filed Aug. 1, 1995 PCT Pub. No. WO96/04275 PCT Pub. Date Feb. 15, 1996The invention relates to the products of formula (I):    <IMAGE>  (I)  in which: R1=represents hydrogen, aryl, arylcarbonyl, arylthio, alkylcarbonyl, R2, R3 represent in particular halogen, mercapto, acyl, carboxy, nitro, cyano, amino, carbamoyl, R4, -OR4 with R4 representing in particular hydrogen, alkyl, alkenyl, alkynyl, acyl, amino, -(CH2)m1-S(O)m2-X-R10 with m1=0 to 4, m2=0 to 2, X represents a single bond or -NH-, -NH-CO-, -NH-CO-NH-, and R10 represents alkyl, alkenyl or aryl, and Y represents optionally substituted aryl, these products being in all isomer forms and salts, their use as medicaments.
Patent IL-117414-A0 (IL)
Title: 4-alkylthio-pyrimidin- 5-ylacetic acid derivatives their preparation and their use as fungicides
IPC: A01N43/78
Filed: 1996-03-08
Abstract: The invention discloses 2-(4-alkylthio-pyrimidin-5-yl)-acetic acid derivatives of formula I <CHEM>  wherein   R1   is C1-4alkyl, R2   is hydrogen, C1-4alkyl, or C3-7cycloalkyl, R3   is a radical <CHEM>     wherein R4   is hydrogen, C1-4alkyl, C1-4haloalkyl, aryl, aryloxy, C3-5alkenyloxy, C3-5alkynyloxy, halogen, cyano, aryl-C1-4alkoxy, aryloxy-C1-4alkyl, heteroaryl, heteroaryloxy, C1-4alkoxy, C1-4alkoxy-C1-4alkoxy, cyano-C1-4alkoxy, C3-5alkenyl, aryloxy-C1-4alkoxy, C3-7cycloalkyl, halo-C3-7cycloalkyl, C3-5alkynyl, C1-4alkoxycarbonyl, -CONR9R10, -O-CONR9R10, or -CR8=N-O-R7 wherein each of the aromatic rings may be optionally substituted; R5   is hydrogen, halogen, C1-4alkoxy or C1-4alkyl, R6   is hydrogen, C1-4alkyl, C1-4alkoxy, cyano, nitro or halogen, R7   is C1-4alkyl, C3-5alkenyl, C3-5alkynyl, or aryl-C1-4alkyl, R8   is hydrogen, C1-4alkyl, C1-4alkoxy, di-C1-4alkylamino, C1-4haloalkyl, halogen, cyano, C1-4alkoxycarbonyl, or C3-7cycloalkyl,   R9 and R10   are independently hydrogen or C1-4alkyl, or together C3-6alkylene or C3-6alkylene interrupted by oxygen or sulfur, and X   is CH or nitrogen; the use of such compounds for the control of phytopathogens, compositions for facilitating such use, and the preparation of the compounds of formula I.
Patent IL-134341-A0 (IL)
Title: Compositions for inducing an immune response containing an hpv protein antigen
IPC: A61K48/00
Filed: 1998-03-20
Abstract: This document describes compositions and methods for inducing an immune response (e.g., a cellular response such as a cell-mediated cytolytic immune response) to a human papillomavirus (HPV) antigen, which can be displayed by HPV or exhibited by infected cells (e.g., cells from cervical and other tumors). The HPV protein can be joined to a stress protein by chemical conjugation or noncovalently using linking moieties, or by fusion (e.g., a recombinant fusion protein). Also described are expression vectors containing sequences encoding HPV antigens and stress proteins, which can be introduced into cells of a subject or cells ex vivo. Also described are compositions that include a stress protein linked to an HPV antigen and another pharmacologically acceptable component and stress protein -HPV antigen fusions and conjugates. These compositions can be used to induce or enhance an immune response against HPV and cells that exhibit HPV antigens, including HPV-associated tumors.
Patent IL-144004-A0 (IL)
Title: A nozzle for supersonic gas flow and an inertia separator
IPC: E21B43/38
Filed: 1999-12-29
Abstract: A nozzle of converging-diverging shape for creating mist flow at supersonic velocity comprising: a throat having a characteristic diameter D*; an inlet having a characteristic diameter D1, positioned a distance L1 upstream of the nozzle throat; and an outlet having a characteristic diameter D2, positioned a distance L2 downstream of the nozzle throat, wherein the ratio of L2/(D2-D*) is larger than 4, but smaller than 250; an inertia separator based thereon, and a method for supersonic separation of one or more components of a predominantly gaseous stream.
Patent IL-144377-A0 (IL)
Title: Essential fatty acids in the prevention of cardiovascular events
IPC: A61P7/02
Filed: 2000-02-07
Abstract: Use of essential fatty acids containing at least 25% of a mixture of eicosapentaenoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA) in the preparation of a medicament for preventing mortality in a patient who had suffered myocardial infarction is new. Independent claims are included for: (i) use of essential fatty acids containing at least 25% of EPA or DHA in the preparation of a medicament for preventing mortality in a patient who had suffered myocardial infarction; (ii) a method for preventing mortality in a patient who has survived myocardial infarction comprising administration of a mixture of essential fatty acids containing at least 25% EPA+DHA; (iii) a method for preventing mortality in a patient who has survived myocardial infarction comprising administration of a mixture of essential fatty acids containing at least 25% of EPA or DHA.
Patent IL-147639-A0 (IL)
Title: Process for the preparation of naproxene nitroxyalkylesters
IPC: C07B61/00
Filed: 2000-07-27
Abstract: 4-nitroxybutyl ester of the 2-(S)-(6-methoxy-2-naphthyl)-propanoic acid having an enantiomeric excess of the (S) form higher than or equal to 97%.
Patent IL-154636-A0 (IL)
Title: Method and apparatus for printing on rigid panels and contoured or textured surfaces
IPC: B41J2/01
Filed: 2001-08-30
Abstract: Ink jet printing is provided onto rigid panels (15) which may have contoured surface (16). Panels (15) are printed using ultraviolet light curable ink and maybe more completely cure and dry the ink to remove by using heating step. Printhead to panel spacing is adjustable to maintain a predetermined constant distance from the printing element to the surface of the panel. Each of printheads (130a, 130d) independently moveable to control the spacing of the printheads from the substrate. Sensors (138) measure the distance from the printhead to the surface of the substrate. UV curing heads may be located on the print headcarriage (129). Cold UV sources may be used to prevent heat deformation of flat or contoured substrates, thereby making spot curing on heat-sensitive substrates.
Patent IL-161655-A0 (IL)
Title: Information content distribution based on privacy and/or personal information
IPC: G06Q20/12
Filed: 2002-05-20
Abstract: The present invention provides methods and apparatus to protect user privacy while accessing information in public places, using both public and personal devices. This is achieved by employing a mechanism that prevents private information from being displayed on public devices. Instead, this type of information is made available only to a user's personal device(s) that the user carries and/or trusts. An example embodiment of the invention shows relevant parts of the information content, referred to also as information documents or simply documents, to multiple devices based on privacy level and user preferences. Embodiments of the present invention also provide personalized services based on privacy levels defined by users. These users can for example be customers of a retail store. The service provided is sometimes also based on user history of accessing information documents. It permits personalized information to be sent to a customer's personal device.